Allan-Herndon-Dudley-Syndrome in Childhood: Is there No Cure?

Stefan Bittmann *

Department of Pediatrics, Ped Mind Institute, Hindenburgring 4, D-48599 Gronau, Germany and Shangluo Vocational and Technical College, Shangluo, 726000, Shaanxi, China.

*Author to whom correspondence should be addressed.


The syndrome, first described in 1944 by William Allan, Florence C. Dudley, and C. Nash Herndon, is a syndrome which results of disturbed formation of two thyroid hormone transporters, MCT8 and Oatp1c1. Nearly 320 individuals of 132 families have been described with MCT-8 deficiency. Since the first individual treatment attempt with LT4 and Propylthiouracil in 2008, the development of therapies for Allan-Herndon-Dudley syndrome (AHDS) has gained momentum in recent years. Treatment strategies range from symptomatic interventions including botulinum toxin injections, levodopa/carbidopa, assistive devices, functional therapies, rehabilitation to replacement therapies (LT3, LT4, DIPTA, TRIAC, TETRAC), and gene therapy. The diagnosis, treatment and cure of Allan-Herndon-Dudley syndrome in childhood remains challenging for the future.

Keywords: MCT8, child, thyroid transporter-analogon, treatment, genetics

How to Cite

Bittmann, Stefan. 2024. “Allan-Herndon-Dudley-Syndrome in Childhood: Is There No Cure?”. Asian Journal of Pediatric Research 14 (7):79-85.


Download data is not yet available.